Phillips Electronics North America Corp. has recalled 71 HeartStart MRx defibrillators produced in September and October 2016 due to a defect that may cause the device to fail, the Food and Drug Administration announced Friday. If used in automated external defibrillator mode after failing, the device will not delivery patient therapy, which may lead to serious patient injury or death, the agency said. For more information and a list of affected devices, see the FDA notice.

Related News Articles

Headline
Civica Rx, the not-for-profit generic drug company, officially opened its headquarters last week in Lehi, Utah.
Blog
We must address the racial, ethnic and socioeconomic disparities that increase the risk of negative perinatal outcomes for women of color.
Blog
AHA Executive Vice President Maryjane Wurth previews AHA’s Team Training Conference, where different interdisciplinary groups from diverse health care settings…
Headline
The Food and Drug Administration today ordered manufacturers to immediately stop selling and distributing surgical mesh products for transvaginal repair of…
Headline
Readmissions penalties for hospitals with the greatest share of dually eligible beneficiaries could fall by an estimated $22.4 million in fiscal year 2019,…
Headline
The Centers for Medicare…